- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Biodesix: Canaccord bestätigt Kaufempfehlung nach starken Q3-Zahlen | 1 | Investing.com Deutsch | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 04.11. | Biodesix stock maintains Buy rating at Canaccord after strong Q3 results | 1 | Investing.com | ||
| 04.11. | Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates | 4 | Seeking Alpha | ||
| 03.11. | Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M | 1 | Seeking Alpha | ||
| 03.11. | Biodesix, Inc.: Biodesix Announces Third Quarter 2025 Results and Highlights | 81 | GlobeNewswire (Europe) | Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million... ► Artikel lesen | |
| 03.11. | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 31.10. | What's Next: Biodesix's Earnings Preview | 2 | Benzinga.com | ||
| 30.10. | Biodesix, Inc.: Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.10. | Biodesix stock rises after expanded Bio-Rad partnership | 1 | Investing.com | ||
| 22.10. | Biodesix to validate ESR1 mutation test for advanced breast cancer | 1 | Investing.com | ||
| 22.10. | Biodesix validiert ESR1-Mutationstest für fortgeschrittenen Brustkrebs | 1 | Investing.com Deutsch | ||
| 22.10. | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | 260 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| 15.10. | Biodesix, Inc.: Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 06.10. | Biodesix, Inc.: Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit | 1 | GlobeNewswire (USA) | ||
| 01.10. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.09. | Canaccord senkt Kursziel für Biodesix auf 20 US-Dollar, bestätigt aber Kaufempfehlung | 2 | Investing.com Deutsch | ||
| 19.09. | Biodesix stock price target lowered to $20 by Canaccord, maintains Buy rating | 1 | Investing.com | ||
| 11.09. | Biodesix, Inc.: Biodesix Announces One-for-Twenty Reverse Stock Split | 126 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock... ► Artikel lesen | |
| 11.09. | BIODESIX INC - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,070 | +0,83 % | Qiagen auf der Jefferies-Konferenz: Wachstumskurs trotz Herausforderungen | ||
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | +5,58 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| BIONTECH | 88,00 | +0,06 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | +0,05 % | Avidity startet Programm für frühzeitigen Zugang zu DMD44-Therapie | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | +1,69 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | +5,80 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| EVOTEC | 5,162 | -0,77 % | Eilmeldung am Abend: EVOTEC SE zeigt unerwartete Stärke | ||
| PRAXIS PRECISION MEDICINES | 189,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? |
BIODESIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,77 % bei einem Aktienkurs von 6,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.